RN-1, a potent and selective lysine-specific demethylase 1 inhibitor, increases γ-globin expression, F reticulocytes, and F cells in a sickle cell disease mouse model

Experimental Hematology

Volumn 43, Issue 7, 2015, Pages 546-553.e3

  Rivers, Angela ^a,b   Vaitkus, Kestis ^a,b   Ruiz, Maria Armila ^a,b   Ibanez, Vinzon ^a,b   Jagadeeswaran, Ramasamy ^a,b   Kouznetsova, Tatiana ^a,b   DeSimone, Joseph ^a,b   Lavelle, Donald ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DECITABINE; ENZYME INHIBITOR; HEMATOLOGIC AGENT; HEMOGLOBIN F; HEMOGLOBIN GAMMA CHAIN; HYDROXYUREA; LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR; MESSENGER RNA; RN 1; TRANYLCYPROMINE; TRANYLCYPROMINE DERIVATIVE; UNCLASSIFIED DRUG; AOF2 PROTEIN, MOUSE; HISTONE; HISTONE DEMETHYLASE; RETINOIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLS BY BODY ANATOMY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ERYTHROID PRECURSOR CELL; F CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETICULOCYTE; SICKLE CELL ANEMIA; ANALOGS AND DERIVATIVES; ANEMIA, SICKLE CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; BABOON; BIOSYNTHESIS; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; ERYTHROPOIESIS; GENE EXPRESSION REGULATION; GENETICS; HEMATOPOIETIC STEM CELL; METABOLISM; METHYLATION; PROTEIN PROCESSING; TRANSGENE; TRANSGENIC MOUSE; U937 CELL LINE;

MUS; PAPIO; PRIMATES;

ANEMIA, SICKLE CELL; ANIMALS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; ERYTHROID PRECURSOR CELLS; ERYTHROPOIESIS; FETAL HEMOGLOBIN; GAMMA-GLOBINS; GENE EXPRESSION REGULATION; HEMATOPOIETIC STEM CELLS; HISTONE DEMETHYLASES; HISTONES; HUMANS; HYDROXYUREA; METHYLATION; MICE; MICE, TRANSGENIC; PAPIO; PROTEIN PROCESSING, POST-TRANSLATIONAL; RETICULOCYTES; TRANSGENES; TRANYLCYPROMINE; TRETINOIN; U937 CELLS;

EID: 84930797171     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2015.04.005     Document Type: Article

References (30)

1. Bunn H. Chapter 7. Human hemoglobins: Sickle hemoglobin and other mutants. The Molecular Basis of Blood Diseases 2001, Saunders, Philadelphia, PA. G. Stamatoyannopoulos (Ed.).
2. Wheatherall D. Chapter 6. The thalassemias. The Molecular Basis of Blood Diseases 2001, Saunders, Philadelphia, PA. G. Stamatoyannopoulos (Ed.).
3. Powars D.R., Weiss J.N., Chan L.S., Schroeder W.A. Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia?. Blood 1984, 63:921-926.
4. Platt O.S., Brambilla D.J., Rosse W.F., et al. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med 1994, 330:1639-1644.
5. Perrine S.P., Pace B.S., Faller D.V. Targeted fetal hemoglobin induction for treatment of beta hemoglobinopathies. Hematol Oncol Clin North Am 2014, 28:233-248.
6. Ingram V.M. Gene mutations in human haemoglobin: the chemical difference between normal and sickle cell haemoglobin. Nature 1957, 180:326-328.
7. Ofori-Acquah S.F., Green B.N., Davies S.C., Nicolaides K.H., Serjeant G.R., Layton D.M. Mass spectral analysis of asymmetric hemoglobin hybrids: demonstration of Hb FS (alpha2gammabetaS) in sickle cell disease. Anal Biochem 2001, 298:76-82.
8. Sunshine H.R., Hofrichter J., Eaton W.A. Requirement for therapeutic inhibition of sickle haemoglobin gelation. Nature 1978, 275:238-240.
9. Atweh G.F., DeSimone J., Saunthararajah Y., et al. Hemoglobinopathies. Hematol Am Soc Hematol Educ Program 2003, 2003:14-39.
10. Suzuki M., Yamamoto M., Engel J.D. Fetal globin gene repressors as drug targets for molecular therapies to treat the beta-globinopathies. Mol Cell Biol 2014, 34:3560-3569.
11. Brawley O.W., Cornelius L.J., Edwards L.R., et al. National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med 2008, 148:932-938.
12. Platt O.S., Orkin S.H., Dover G., Beardsley G.P., Miller B., Nathan D.G. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 1984, 74:652-656.
13. Amente S., Lania L., Majello B. The histone LSD1 demethylase in stemness and cancer transcription programs. Biochim Biophys Acta 2013, 1829:981-986.
14. Kerenyi M.A., Shao Z., Hsu Y.J., et al. Histone demethylase Lsd1 represses hematopoietic stem and progenitor cell signatures during blood cell maturation. Elife 2013, 2:e00633.
15. Sprussel A., Schulte J.H., Weber S., et al. Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation. Leukemia 2012, 26:2039-2051.
16. Shi L., Cui S., Engel J.D., Tanabe O. Lysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin induction. Nat Med 2013, 19:291-294.
17. Xu J., Bauer D.E., Kerenyi M.A., et al. Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A. Proc Natl Acad Sci U S A 2013, 110:6518-6523.
18. Omori A., Tanabe O., Engel J.D., Fukamizu A., Tanimoto K. Adult stage gamma-globin silencing is mediated by a promoter direct repeat element. Mol Cell Biol 2005, 25:3443-3451.
19. Cui S., Kolodziej K.E., Obara N., et al. Nuclear receptors TR2 and TR4 recruit multiple epigenetic transcriptional corepressors that associate specifically with the embryonic beta-type globin promoters in differentiated adult erythroid cells. Mol Cell Biol 2011, 31:3298-3311.
20. Sankaran V.G., Menne T.F., Xu J., et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science 2008, 322:1839-1842.
21. Xu J., Sankaran V.G., Ni M., et al. Transcriptional silencing of {gamma}-globin by BCL11A involves long-range interactions and cooperation with SOX6. Genes Dev 2010, 24:783-798.
22. Neelamegam R., Ricq E.L., Malvaez M., et al. Brain-penetrant LSD1 inhibitors can block memory consolidation. ACS Chem Neurosci 2012, 3:120-128.
23. Schenk T., Chen W.C., Gollner S., et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med 2012, 18:605-611.
24. Lavelle D., Vaitkus K., Ruiz M.A., et al. Effect of AGM and fetal liver-derived stromal cell lines on globin expression in adult baboon (P.anubis) bone marrow-derived erythroid progenitors. PLoS One 2012, 7:e36846.
25. Liu J., Zhang J., Ginzburg Y., et al. Quantitative analysis of murine terminal erythroid differentiation invivo: novel method to study normal and disordered erythropoiesis. Blood 2013, 121:e43-e49.
26. Palii S.S., Van Emburgh B.O., Sankpal U.T., Brown K.D., Robertson K.D. DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol 2008, 28:752-771.
27. Orta M.L., Dominguez I., Pastor N., Cortes F., Mateos S. The role of the DNA hypermethylating agent budesonide in the decatenating activity of DNA topoisomerase II. Mutat Res 2010, 694:45-52.
28. Hojfeldt J.W., Agger K., Helin K. Histone lysine demethylases as targets for anticancer therapy. Nat Rev Drug Discov 2013, 12:917-930.
29. Wang J., Hevi S., Kurash J.K., et al. The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nat Genet 2009, 41:125-129.
30. Roosjen M., McColl B., Kao B., Gearing L.J., Blewitt M.E., Vadolas J. Transcriptional regulators Myb and BCL11A interplay with DNA methyltransferase 1 in developmental silencing of embryonic and fetal beta-like globin genes. FASEB J 2014, 28:1610-1620.